Finasteride Linked to Fewer Complications After Severe Heart Attack

What Happened

A registry study from the University of Gothenburg reported that men taking finasteride for benign prostatic hyperplasia (BPH) at the time of a severe acute heart attack had fewer serious complications after the event.

The study focused on men with ST-elevation myocardial infarction (STEMI) who underwent balloon angioplasty, a common procedure used to rapidly open blocked coronary vessels.

• Source publication: JAMA Network Open (2026)
• Population: Swedish men with STEMI treated with balloon angioplasty
• Exposure of interest: finasteride use for BPH at the time of the heart attack

What The Evidence Shows In This Study

This was a registry study using the SWEDEHEART quality registry and national registers, not a randomized clinical trial.

Researchers matched men treated with androgen-modulating drugs to similar men who had a heart attack but did not receive those treatments, aiming to make groups as comparable as possible aside from the drug exposure.

• Serious complications occurred in 20.8% of men treated with finasteride vs 24.3% of matched controls.
• The study defined serious complications as cardiac arrest, severe conduction disturbances affecting heart rhythm and pumping ability, severely impaired left ventricular function, or death within 30 days.
• No significant difference was observed among patients treated with hormone medication for prostate cancer.

Why A Prostate Drug Might Be Relevant To Hormones And Heart Damage

The report notes that studies have shown male sex hormones such as testosterone can intensify inflammation during an acute heart attack and are linked to a larger area of damage in men.

Finasteride is a 5-alpha-reductase inhibitor that blocks the enzyme converting testosterone into dihydrotestosterone (DHT), described as a more potent and biologically active form of testosterone.

• Inflammation is described as a key factor in the extent of heart damage when an acute heart attack is treated with balloon angioplasty.
• Finasteride is used to reduce the size of an enlarged prostate in BPH by lowering DHT via enzyme blockade.

Practical Context For Metabolic-Health Readers

For readers tracking hormones and cardiometabolic risk, the study adds human registry evidence that androgen-modulating therapy for BPH coincided with fewer serious short-term complications after STEMI in this specific Swedish population.

The researchers cautioned that the finding does not directly change patient treatment at present, even though it aligns with their hypothesis about sex hormones and heart outcomes.

• Applies to: men with severe acute heart attack (STEMI) treated with balloon angioplasty in Sweden.
• Outcome window: serious complications or death within 30 days.
• Interpretation offered in the report: a potential link between sex-hormone pathways, inflammation, and heart-attack injury.

Limitations And What To Watch Next

Because this was an observational registry study, it can show an association but cannot prove that finasteride caused the lower complication rate.

The results are specific to the studied group and setting, and the report notes no significant difference in patients on hormone medication for prostate cancer, which may matter when considering how different androgen-modulating approaches relate to heart outcomes.

• Study design: registry-based matching, not random assignment to treatment.
• Scope: men with STEMI undergoing balloon angioplasty; the report does not claim results for other heart-attack types or treatments.
• Clinical impact statement in the report: “it has no direct impact on patient treatment at present.”